Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
Curr Vasc Pharmacol. 2016 Sep 9;
Authors: Athyros VG, Katsiki N, Tentolouris N
PMID: 27633290 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Athyros VG, Katsiki N, Tentolouris N Tags: Curr Vasc Pharmacol Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Heart | Victoza